Lates News

date
27/04/2025
According to CBN News, Huajin Securities issued a research report on April 26, giving Lifan Pharmaceutical (002734.SZ) a buy rating. The main reasons for the rating include: 1) distinctive layout in agricultural and animal medicines; 2) increase in product prices driving performance improvement; 3) optimized research and development strategic layout, accelerating the transformation of results.
Latest
See all latestmore